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H I G H L I G H T S
• mGluR5 activation with DHPG and VU0092273 showed neuroprotective effects in OGD.• mGluR5 exerted its neuroprotective effects via PI3K/Akt pathway.• mGluR5 also prevented the GluA2 down-regulation following an ischemic injury.• mGluR5 appears to stimulate neuroprotective responses in astrocytes and microglia.
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A B S T R A C T
Previous studies have demonstrated that antagonists of mGluR1, but not mGluR5, are neuroprotective in models
of cerebral ischemia. To investigate the individual roles of mGlu1 and mGlu5 receptors in in vitro model of
cerebral ischemia we used low doses of the non-selective group I agonist DHPG and mGlu1 and mGlu5 selective
positive allosteric modulators (PAMs). In hippocampal slices subjected to 30min oxygen-glucose deprivation
(OGD), DHPG (1 μM) and the mGluR5 PAM (VU0092273) significantly reduced OGD-induced CA1 injury
monitored by propidium iodide staining of the slices and quantitative analysis of CA1 neurons. In contrast, the
mGluR1 PAM (VU0483605) showed no neuroprotection. These protective effects of DHPG and VU0092273 were
prevented by inhibition of PI3K/Akt pathway by LY294002. The mGluR5 PAM (VU0092273) also prevented
GluA2 down-regulation triggered by ischemic injury, via PI3K/Akt pathway, revealing a further contribution to
its neuroprotective effects by reducing the excitotoxic effects of increased Ca2+ influx through GluA2-lacking
AMPA receptors. Furthermore, immunohistochemical assays confirmed the neuroprotective effect of VU0092273
and revealed activation of glia, indicating the involvement reactive astrogliosis in the mechanisms of neuro-
protection. Our data suggest that selective activation/potentiation of mGluR5 signalling represents a promising
strategy for the development of new interventions to reduce or prevent ischemia-induced neuronal death.
1. Introduction
Ischemia caused by stroke is one of the main causes of mortality and
long-term disability worldwide (Law et al., 2017). Massive glutamate
release following an ischemic injury triggers an excitotoxic cascade,
which leads to glutamate receptor-mediated delayed cell death of vul-
nerable neuronal populations (Buchan and Pulsinelli, 1990).
Metabotropic glutamate (mGlu) receptors are classified into three
subgroups (Groups I, II and III) based on sequence homology, signalling
transduction pathways and relative pharmacology (Conn and Pin,
1997). Of these, group I comprises mGlu1 and mGlu5, which coupled to
Gq/11 and mediate IP3/Ca2+ signal transduction via phospholipase C
(PLC) activation (Abe et al., 1992). Although the two subtypes of group
I metabotropic glutamate receptors are highly homologous, they play
different roles in the cerebral ischemia. mGlu1, but not mGlu5, an-
tagonists are neuroprotective in models of cerebral ischemia (Pellegrini-
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Giampietro, 2003). In addition, mGlu5 is expressed on astrocytes where
it contributes to the modulation of synaptic transmission efficacy and
local blood flow (Arizono et al., 2014) and on microglia where it
mediates numerous actions essential for intrinsic glial cell function, as
well as for glial–neuronal interactions (Loane et al., 2012).
Positive allosteric modulators, PAMs, are compounds that interact
at “allosteric” sites, topographically distinct from the orthosteric site,
where they can affect the affinity and/or efficacy of an orthosteric li-
gand, a property referred to as cooperativity. This is useful because the
allosteric site contains a higher level of sequence diversity between
receptor subtypes than the orthosteric site, allowing for greater subtype
selectivity of allosteric ligands (Christopoulos and Kenakin, 2002; Conn
et al., 2009). Moreover, allosteric agents have the potential to show
differential effects on downstream signalling pathways, termed func-
tional selectivity. Thus, PAMs provide a potential opportunity to de-
velop agents that selectively target GPCR signalling pathways critical
for therapeutic efficacy without modulating signalling pathways that
lead to adverse effects (Nickols and Conn, 2014).
To better discriminate the role of group I metabotropic glutamate
receptors we used the non-selective agonist DHPG and two selective
positive allosteric modulators (PAMs), mGluR1 PAM 3-chloro-N-(3-
chloro-4-(4-chloro-1,3-dioxoioindolin-2-yl)picolinamide, VU0483605,
and the mGluR5 PAM (4-hidroxypiperidin-1-yl)(4-(phenylethynyl)
phenyl)methanone, VU0092273, in the in vitro model of OGD. Our
results show that selectively enhancing mGluR5 signalling can be
neuroprotective against neuronal death in CA1 via a mechanism that
involves both activation of the PI3K/Akt pathway and the prevention of
the GluA2 AMPA subunit down-regulation induced by OGD.
2. Materials and methods
Experiments and animal use procedures were in accordance with
the National Institutes of Health Guide for the Care and Use of
Laboratory Animals (NIH Publications No. 80-23, revised 1996). The
experimental protocols were approved by the Animal Committee of the
Department of Pharmacology, University of Florence, in compliance
with the European Convention for the Protection of Vertebrate Animals
used for Experimental and Other Scientific Purposes (ETS No. 123) and
the European Communities Council Directive of 24 November 1986
(86/609/EEC). The authors further attest that all efforts were made to
minimize the number of animals used and their suffering.
2.1. Materials
(S)-3,5-Dihydroxyphenylglycine (DHPG), (S)-(+)-α-amino-4-car-
boxy-2-methylbenzeneacetic acid (LY367385) and 2-methyl-6-(pheny-
lethynyl)pyridine hydrochloride (MPEP) were purchased from Tocris
Cookson (Bristol, UK). 1-Naphthylacetyl spermine trihydrochloride
(NASPM) was purchased from Sigma-Aldrich, St. Louis, MO, USA). 3-
Chloro-N-[3-chloro-4-(4-chloro-1,3-dihydro-1,3-dioxo-2H-isoindol-2-
yl)phenyl]-2-pyridinecarboxamide (VU0483605) and (4-hydro-
xypiperidin-1-yl)-[4-(2-phenylethynyl)phenyl]methanone
(VU0092273) were generously provided by Dr. Jeffrey P. Conn
(Vanderbilt University Medical Center, Nashville, TN, USA).
2-(4-Morpholinyl)-8-(4-aminophenyl)-4H-1-benzopyrone-4-one (LY
294002) was purchased from Calbiochem (Merck Biosciences Ltd,
Nottingham, UK). Propidium iodide (PI) was purchased from Molecular
Probes (Leiden, the Netherlands) and tissue culture reagents were ob-
tained from Gibco-BRL (San Giuliano Milanese, MI, Italy) and Sigma (St
Louis, MO, USA).
2.2. Oxygen-glucose deprivation in organotypic hippocampal slice cultures
Organotypic hippocampal slice cultures were prepared as previously
reported in detail (Gerace et al., 2012). Briefly, hippocampi were re-
moved from the brains of 7–9 days old Wistar rats (Harlan, MI, Italy),
and transverse slices (420 μm) were prepared using a McIlwain tissue
chopper. Slices were then transferred onto 30mm diameter semiporous
membranes inserts (Millicell-CM PIC M 03050; Millipore, Italy), which
were placed in six-well tissue culture plates containing 1.2ml culture
medium per well. Slices were maintained at 37 °C in an incubator in
atmosphere of humidified air and 5% CO2 and the culture medium was
Fig. 1. Dose-dependent effects of DHPG
against OGD injury in rat organotypic hip-
pocampal slices. (A) Schematic diagram
showing that slices were incubated with
mGlu receptor agonists and antagonists
during OGD and the subsequent recovery
period. Twenty-four h later slices were in-
cubated with PI for fluorescence detection
of their optical density. (B) Hippocampal
slices, photographed under fluorescence
optics, displaying background levels of
fluorescence under control conditions, an
intense PI labeling in the CA1 sub-region
24 h after exposure to 30 min OGD, a re-
duction in PI fluorescence when incubated
with 1 μM DHPG, that was prevented by the
mGlu5 antagonist MPEP but not by the
mGlu1 antagonist LY367385, and a marked
increase in OGD-induced PI fluorescence
when incubated with 300 μM DHPG. (C)
Quantitative analysis of OGD-induced CA1
PI fluorescence expressed as percentage of
OGD toxicity. Incubation with 1 μM DHPG
significantly attenuated OGD injury; the
effect was completely reverted by the co-
incubation with the mGlu5 antagonist
MPEP (10 μM) but not with the mGlu1 an-
tagonist LY367385 (100 μM). Incubation
with 10 μM DHPG had no effect whereas
100 and 300 μM DHPG exacerbated OGD injury. Values represent the mean ± SEM of at least three experiments performed in quadruplicate. **P < 0.01 and
*P < 0.05 vs. 30 min OGD alone (ANOVA + Tukey's w-test).
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changed thrice a week. Experiments were carried out after 14 days in
vitro. The slices were subjected to OGD by exposing them to a serum-
and glucose-free medium saturated with 95% N2 and 5% CO2 at 37 °C
in an airtight anoxic chamber equipped with an oxygen gas controller
(BioSpherix, New York, USA). After 30min, the cultures were trans-
ferred to oxygenated serum-free medium containing 5mg/ml glucose
and maintained at 37 °C, 35 °C or 32 °C in different incubators under
normoxic conditions until neuronal injury was evaluated 24 h later.
Drugs were present in the incubation medium during OGD and the
subsequent 24 h recovery period (Fig. 1A). Cell injury was assessed by
using the fluorescent dye PI (5 μg/ml); fluorescence was viewed using
an inverted fluorescence microscope. Images were digitized using a
video image controlled by software and subsequently analysed using a
morphometric analysis software. In order to quantify cell death, the
CA1 hippocampal subfield was identified and encompassed in a frame
using the drawing function in the image software (ImageJ; NIH, Be-
thesda, USA) and the optical density of PI fluorescence was detected.
Control experiments performed in our laboratory, as well as a number
of previous studies using organotypic hippocampal slices exposed to
ischemia-related insults, have shown that there is a linear correlation
between relative PI fluorescence and the number of injured cells as
detected by morphological criteria (Gerace et al., 2012).
2.3. Western blot analysis
Hippocampal slices were washed with cold 0.01M phosphate-buf-
fered saline, pH 7.4 and 4 slices/sample were gently transferred and
dissolved in a tube containing 1% sodium dodecyl sulfate (SDS) as
previously reported in detail (Gerace et al., 2016; Landucci et al.,
2016). Total protein levels were quantified using the Pierce (Rockford,
IL, USA) BCA (bicinchoninic acid) Protein Assay. Homogenates (40 μg
of protein) were resolved by electrophoresis on 4–20% (wt/vol) SDS-
polyacrylamide gel (Bio-Rad Laboratories, Hercules, CA, USA) and
transferred onto nitrocellulose membranes using the transblot TURBO
(Bio-Rad, Hercules, CA, USA). Blots were blocked for 1 h at room
temperature in Tris-buffered saline, pH 7.6, 0.1% Tween 20 (TBS-T)
containing 5% non-fat dry milk, and then incubated overnight at 4 °C
with a polyclonal rabbit antibody directed against phospho-Akt
(Ser473) or phospho-GSK3-β (Ser9) (all from Cell Signalling Tech-
nology, Beverly, MA, USA) diluted 1:1000 in TBS-T containing 5%
bovine serum albumin and polyclonal goat anti-GluA2 (Santa Cruz
Biotechnology, Paso Robles, CA, USA) diluted 1:1000 in TBS-T con-
taining non-fat dry milk. Monoclonal α-tubulin antibody (Sigma,
1:5000) was used as loading control. Immunodetection was performed
with secondary antibodies (1:2000 anti-rabbit, anti-goat and anti-
mouse IgG from donkey; Amersham Biosciences, Buckinghamshire,
UK)) conjugated to horseradish peroxidase. The reactive bands were
detected using chemiluminescence (ECLplus; Euroclone, Padova, Italy).
Quantitative analysis was performed using the QuantityOne analysis
software (Bio-Rad, Hercules, CA, USA).
2.4. Triple labelling immunohistochemistry
Organotypic hippocampal slices were triple immunostained with
the free floating method as described (Lana et al., 2014). Briefly, after
blocking with Blocking Buffer (BB), slices were incubated overnight
under agitation with the following primary antibodies: a mouse
monoclonal anti-neuronal nuclei (NeuN, 1:200, Millipore, Billerica,
MA, USA) for neurons, and a rabbit polyclonal anti IBA1, (1:300,
WAKO, Osaka, Japan) for microglia, both diluted in BB solution. IBA1
(Ionized calcium binding adaptor molecule 1) is an intracellular 17-kDa
protein whose expression is restricted to microglia/macrophages (Imai
et al., 1996) Iba1 is a protein for cytoskeletal rearrangement in mi-
croglia, widely used as a specific marker for total microglia. All the
following steps were done at room temperature in the dark for 2 h. After
washings, slices were incubated with an anti-rabbit secondary antibody
conjugated with AlexaFluor 635 (for microglia, 1:400, Thermo Fisher
Sci., Waltham, MA, USA). After incubation, a secondary antibody
conjugated with AlexaFluor 555 (for neurons, 1:400, Thermo Fisher
Sci.) was added, and slices were incubated as above. Finally, astrocytes
were immunostained with a primary monoclonal anti GFAP antibody
conjugated with AlexaFluor 488 (1:500, Millipore). Glial Fibrillary
Acidic Protein (GFAP), is a structural protein (Bignami et al., 1972) a
key component of the astrocyte's cytoskeleton, and classically used as a
marker for astrocytes (Middeldorp and Hol, 2011). After washings, the
slices were mounted with Vectashield mounting medium with DAPI
(Vector Laboratories, Burlingame, CA, USA).
2.5. Confocal laser scanning microscopy and quantitative analysis
Images were acquired under a LEICA TCS SP5 confocal laser scan-
ning microscope (Leica Microsystems CMS GmbH, Mannheim,
Germany) with a 20X objective. Confocal scans were taken at 1 μm z-
steps keeping all parameters (pinhole, contrast and brightness) con-
stant. Image analyses were conducted on z-stacks which contained the
region of interest, corresponding to the CA1 area. Images were digitally
converted to green, red or blue using Image J (National Institute of
Health, http://rsb.info.nih.gov/ij).
Quantification of astrocytes, neurons and microglia immuno-
fluorescence was performed separately using Image J. Three con-
secutive z-scans (1 μm each, total 3 μm) were stacked, starting at 10 μm
inside the slice and an appropriate and constant threshold level was
selected. Quantitation of immunofluorescence of NeuN, GFAP or IBA1
was then obtained from the ratio between positive pixels above
threshold and total pixels in each region of interest.
2.6. Statistical analysis
Data are presented as means ± SEM of n experiments. Statistical
significance of differences were analysed using one-way ANOVA fol-
lowed by the post hoc Dunnet and Tukey's w-test for multiple com-
parisons. All statistical calculations were performed using GRAPH-PAD
PRISM v. 5 for Windows (GraphPad Software, San Diego, CA, USA). A
probability value (P) of< 0.05 was considered significant.
3. Results
3.1. Activation of mGlu5 receptors is neuroprotective in rat organotypic
hippocampal slices exposed to OGD
We have reported previously that the nonselective group I mGlu
receptor agonist DHPG at 100 and 300 μM exacerbates OGD injury in
organotypic hippocampal slices (Pellegrini-Giampietro et al., 1999) and
that this toxic effect is most likely mediated by mGlu1 rather than
mGlu5 receptors (Pellegrini-Giampietro, 2003). On the other hand, we
observed that DHPG induces ischemic tolerance at subtoxic (< 10 μM)
concentrations in the same model via the contribution of both mGlu1
and mGlu5 receptors (Werner et al., 2007). Therefore, in this study
examined whether low, subtoxic concentrations of DHPG could also
protect organotypic hippocampal slices against OGD injury.
Consistent with our previous observations (Pellegrini-Giampietro
et al., 1999; Meli et al., 2002), when relatively high concentrations of
DHPG (100–300 μM) were added to the incubation medium of hippo-
campal slices during OGD and the 24 h recovery period the damage in
the CA1 region induced by simulated ischemia was significantly en-
hanced (Fig. 1). Conversely, a low concentration of DHPG (1 μM) pro-
duced a 30% reduction in OGD injury that was completely prevented by
the mGlu5 antagonist MPEP (10 μM) but not by the mGlu1 antagonist
LY367385 (100 μM). An intermediate concentration of DHPG (10 μM)
was neither toxic nor neuroprotective under our experimental condi-
tions.
To corroborate the contribution of mGlu5 receptors in the
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protective effects of DHPG, we compared the effects of VU0483605, a
positive allosteric modulator (PAM) of mGlu1 receptors with an EC50 of
350 nM (Cho et al., 2014), and VU0092273, a PAM of mGlu5 receptors
with an EC50 of 10 nM (Noetzel et al., 2012). In hippocampal slices
exposed to 30min OGD, the mGlu1 PAM VU0483605 (1 μM) did not
reduce OGD injury when present during the 30min of OGD and the
subsequent 24 h recovery period. Moreover, there was no effect of the
mGlu1 antagonist LY367385 (100 μM) (Fig. 2). On the other hand, the
mGlu5 PAM VU0092273 (10 nM) reduced PI fluorescence in the CA1
area by approximately 50%, and this protective effect was reversed by
the mGlu5 antagonist MPEP (10 μM) (Fig. 2).
3.2. Effects of the activation of mGlu5 receptors on neurons, astrocytes and
microglia in the CA1 subregion of rat organotypic hippocampal slices
exposed to OGD
We next assessed the effects of DHPG and VU0092273 on both CA1
pyramidal cell viability and astrocyte and microglia proliferation by
using triple immunostaining for NeuN, GFAP and IBA1 on organotypic
slices harvested 24 h after 30min OGD, followed by confocal micro-
scopy. Representative images are shown in Fig. 3 (red for neurons,
green for astrocytes and blue for microglia) obtained from triple im-
munostaining experiments performed on the same slice exposed to
control conditions (Fig. 3. A1-C1a), 30min OGD (Fig. 3. A2-C2a),
30min OGD in the presence of 1 μM DHPG (Fig. 3. A3-C3a), and 30min
OGD in the presence of 10 nM VU009227 (Fig. 3. A4-C4a).
NeuN immunostaining (Fig. 3. A1-A4 and 3D) confirmed that via-
bility of CA1 pyramidal neurons exposed to 30min OGD was sig-
nificantly decreased (by 32%) as compared to control slices. This loss of
neurons was prevented by 1 μM DHPG and 10 nM VU0092273. Con-
versely, GFAP immunostaining (Fig. 3. B1–B4 and 3E) showed that
astrocytes were not significantly affected 24 h after OGD injury.
Quantitative analysis (Fig. 3E) demonstrated that both treatments with
DHPG (+41% vs. control) and VU0092273 (+62% vs. control) in-
creased GFAP levels in CA1 24 h after OGD, but only the effect of
VU0092273 was statistically significant. Higher resolution images of
the indicated areas (Fig. 3. B1a-B4a) indicate that, after treatment with
VU0092273, astrocytes were distributed in overlapping domains,
showed morphological changes such as hypertrophy of the cell body
and processes (Fig. 3B4a, open arrow), and displayed increased ex-
pression of GFAP, conditions that resemble those defined as adaptive
reactive astrocytosis (Burda and Sofroniew, 2014; Sofroniew, 2015;
Choudhury and Ding, 2016).
Quantitative analysis of IBA1 immunostaining (Fig. 3, C1–C4 and F)
showed that the density of microglia in CA1 was not modified 24 h after
OGD. Treatment with DHPG and VU0092273 significantly increased
microglia proliferation by 44.5% and 65%, respectively, in comparison
to controls (Fig. 3F). The magnifications of the framed areas of panels
C1–C4 (Fig. 3. C1a-C4a) show that in OGD slices treated with DHPG
and VU0092273 microglia cells display a morphology typical of re-
active microglia (Milligan and Watkins, 2009; Cerbai et al., 2012; Lana
et al., 2014). In particular, some microglia cell bodies were enlarged
and had amoeboid shape (Fig. 3. C4a, open arrow), highlighted by the
dotted lines in the magnification of cell body (Fig. 3 C4b, open arrow),
others were rod-shaped (Fig. 3. C3a, white arrow),highlighted by the
dotted lines in the magnification of cell body (Fig. 3 C3b, white arrow)
and their cellular branches were shorter, de-ramified and twisted. This
effect was present, albeit to a lesser extent, in untreated OGD slices
(Fig. 3. C2a).
3.3. The PI3K–Akt signalling pathway mediates the protective effects
induced by mGlu5 receptors
Allosteric agents have the potential to exert differential effects on
downstream signalling, a phenomenon termed functional selectivity
(Nickols and Conn, 2014). Interestingly, we have shown previously in
rat organotypic hippocampal slices that activation of the phosphatidy-
linositol 3-kinase (PI3K) signalling pathway with the subsequent acti-
vation by phosphorylation of the pro-survival protein kinase Akt are
implicated in the neuroprotective mechanisms of DHPG pre-
conditioning (Scartabelli et al., 2008). We tested if the neuroprotective
effects evoked by mGlu5 receptor activation with a selective PAM were
mediated by this kinase signalling cascade. Fig. 4A shows that the PI3K
inhibitor LY294002 at 10 μM prevented the neuroprotective effects of
both 1 μM DHPG and 10 nM VU0092273, indicating that PI3K activa-
tion is involved in the mechanisms following mGlu5 activation. To
examine the downstream effectors of PI3K activation, we used phospho-
specific antibodies to measure the relative levels of the phosphorylated,
active form of Akt and of the phosphorylated, inactive form of GSK3-β
in hippocampal slices 24 h after OGD (Fig. 4B and C). Exposure to OGD
induced a marked reduction in the phosphorylation of both Akt (by
68%) and GSK3-β (by 60%), that was completely prevented by co-
Fig. 2. The mGlu5 receptor PAM VU0092273 but not
the mGlu1 receptor PAM VU0483605 attenuates
OGD injury in hippocampal slices. The experiments
were carried out and drugs were added as shown in
Fig. 1A. (A) Hippocampal slices, photographed under
fluorescence optics, displaying selective damage of
the CA1 subregion 24 h following 30 min OGD and a
reduction in PI fluorescence when incubated with the
mGlu5 receptor PAM VU0092273, that was reverted
by the mGlu5 antagonist MPEP, but not with the
mGlu1 receptor PAM VU0483605. (B) Quantitative
analysis of OGD-induced CA1 PI fluorescence ex-
pressed as percentage of OGD toxicity. Incubation
with 10 nM VU0092273 significantly attenuated
OGD injury; the effect was reverted by co-incubation
with the mGlu5 antagonist MPEP (10 μM). The
mGlu1 receptor PAM VU 0483605 (1 μM) incubated
alone or in combination with the mGlu1 antagonist
LY367385 (100 μM) had no effect on OGD injury.
Values represent the mean ± SEM of at least three
experiments performed in quadruplicate.
**P < 0.01 vs. 30 min OGD alone (ANOVA + Tu-
key's w-test).
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incubation with the mGlu5 PAM VU0092273 (10 nM) but not the
mGlu1 PAM VU0483605 (1 μM). The PI3K inhibitor LY294002 at
10 μM was able to revert the effects of PAM VU0092273, indicating that
the mGlu5-mediated increases in the phosphorylation of Akt and GSK3-
β requires activation of the PI3K-Akt cascade.
3.4. Activation of mGlu5 receptors prevents the down-regulation of the
GluA2 AMPA receptor subunit induced by OGD
We have previously shown that OGD induces a down-regulation in
the protein expression of the GluA2 subunit of AMPA receptors in or-
ganotypic hippocampal slices prior to CA1 pyramidal cell death
(Llorente et al., 2015). This phenomenon has been designated as the
AMPA receptor ‘molecular switch’, that is triggered by cerebral
ischemia and other neurological disorders and leads to the formation of
GluA2-lacking Ca2+-permeable AMPA receptor channels and neurode-
generation in cells destined to die (Pellegrini-Giampietro et al., 1997;
Liu et al., 2006; Henley and Wilkinson, 2016; Koszegi et al., 2017).
Twelve hours after OGD, a time point preceding CA1 neuronal death,
Western blot analysis confirmed that the protein expression of the
Fig. 3. Effects of DHPG and VU0092273 on neurons, astrocytes and microglia in the CA1 area of organotypic hippocampal slices 24 h after exposure to 30 min OGD.
Merge1-4: Representative confocal images of merged immunostaining of neurons (NeuN), astrocytes (GFAP) and microglia (IBA1) in control (Merge 1), OGD (Merge
2), OGD + DHPG (Merge 3) and OGD + VU0092273 (Merge 4). The images shown in Fig. 3A1–A4 (neurons), 3B1–B4 (astrocytes), and 3C1–C4 (microglia) are
obtained stacking 3 consecutive confocal z-scans (1 μm z-step each, total 3 μm) taken at 10 μm depth inside the slice. Images A1-C1a, A2-C2a, A3-C3a and A4-C4a are
split images from a triple immunostaining performed on the same slice per experimental group. Scale bars: A1-A4, B1–B4, C1–C4: 100 μm B1a-B4a, C1a-C4a:
magnifications of the framed areas in the above panels. Scale bars: 15 μm C3b-C4b: magnifications of the microglial cells pointed by the arrows in panels C3a and
C4a, respectively. The dotted lines highlight the outlines of the microglial cells. Scale bars: 7.5 μm. D: NeuN fluorescence intensity of CA1 pyramidal neurons.
**P < 0.01 vs. control (ANOVA + Tukey's w-test). E: GFAP fluorescence intensity in CA1. *P < 0.05 vs. control (ANOVA + Tukey's w-test). E: IBA1 fluorescence
intensity in CA1. **P < 0.01 and *P < 0.05 vs. control (ANOVA+ Tukey's w-test). Values on the y axes are ratios between positive pixels above threshold and total
pixels of regions of interest and represent the mean ± SEM of at least three experiments performed in quadruplicate.
Fig. 4. The PI3K–Akt signalling pathway mediates the protective effects evoked by mGlu5 receptors. (A) The PI3K inhibitor LY294002 prevents the neuroprotective
effects induced by mGlu5 activation. Top: Hippocampal slices, photographed under fluorescence optics, displaying increased PI fluorescence in the CA1 subregion
24 h after 30min OGD and a marked reduction of neuronal injury when incubated with 1 μM DHPG and 10 nM VU0092273, that was partially prevented by 10 μM
LY294002. Bottom: Quantitative analysis of CA1 PI fluorescence showing that OGD injury was reduced, in a manner that was prevented by 10 μM LY294002, when
slices were co-incubated with 1 μM DHPG or 10 nM VU0092273. Bars represent the mean SEM of at least four experiments run in triplicate. **P < 0.01 and
*P < 0.05 vs. 30 min OGD alone (ANOVA+ Tukey's w-test). (B–C) Activation of mGlu5 receptors prevents the decrease in Akt and GSK3-β phosphorylation induced
by 30 min OGD. Slices were exposed to the OGD for 30 min and processed for Western blotting 24 h later. The mGlu receptor PAMs VU0483605 (1 μM) and
VU0092273 (10 nM) and the PI3K inhibitor LY294002 (10 μM) were added to the incubation medium during OGD and the subsequent 24 h recovery period. Top:
representative Western blots using polyclonal rabbit antibodies directed against phospho-Akt (Ser473) (B) or phospho-GSK3-β (Ser9) (C). The numbers on the right
indicate the estimated molecular mass (kDa). α-Tubulin was used as loading control. Bottom: quantitative analysis of immunoreactive bands, showing that 30 min
OGD induced a significant decrease in the phosphorylation of Akt (B) and GSK3-β (C), that was prevented by the mGlu5 PAM VU0092273 but not the mGlu1 PAM
VU0483605. The PI3K inhibitor LY294002 almost completely reverted the effects of VU0092273. Data are expressed as percentage of control phosphorylation in
control untreated slices. Bars represent the mean ± SEM of three experiments. **P < 0.01 vs. control (ANOVA + Tukey's w test).
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crucial GluA2 subunit that confers Ca2+ impermeability to AMPA re-
ceptor channels, was down regulated by 41% (Fig. 5A). The formation
of GluA2-lacking AMPA receptors leading to neurodegeneration in our
hippocampal slices was confirmed using NASPM, a selective blocker of
Ca2+-permeable AMPA channels, that was able to dose-dependently
attenuate the neuronal injury observed 24 h after OGD (Fig. 5B).
Because activation of group I mGlu receptors has been shown to
reverse the formation of Ca2+-permeable AMPA channels in cocaine-
treated mice ex vivo (Bellone and Lüscher, 2006), we explored whether
activation of mGlu receptors in our hippocampal slices could modify
the changes in expression of AMPA receptor subunits observed fol-
lowing OGD. Interestingly however, the down-regulation of the GluA2
protein induced by OGD could be prevented only by the mGlu5 PAM
VU0092273, suggesting that mGlu5 activation is responsible for the
deleterious AMPA molecular switch that leads to OGD injury. We also
examined whether the PI3K/Akt pathway could mediate the effects of
mGlu receptor activation on the down-regulation of the GluA2 subunit
induced by OGD. Interestingly, the PI3K inhibitor LY294002 (10 μM)
was able to prevent the reversion of the GluA2 down-regulation in-
duced by the mGlu5 PAM VU0092273, but not that induced by DHPG
and the mGlu1 PAM VU0483605 (Fig. 5A).
4. Discussion
In this study, we show that mGlu5 receptor exerts neuroprotective
effects against OGD-induced CA1 injury in rat organotypic hippocampal
slices. Using the non-selective group I mGlu agonist DHPG and the
mGlu5 selective positive allosteric modulator (PAM) VU0092273 we
observed significant reductions in OGD-induced CA1 injury. In contrast
the mGlu1 selective PAM VU0483605 had no protective effect.
Moreover, the protective actions of DHPG and VU0092273 were
blocked by the mGlu5 antagonist MPEP, but not by the mGlu1 an-
tagonist LY367385.
Immunohistochemistry revealed that DHPG and VU0092273 in-
creased the viability of CA1 neurons exposed to OGD and enhanced glia
responses, as demonstrated by the hypertrophy of astrocytes processes,
and by the amoeboid-shape of microglia cell bodies. It is known that the
response of astrocytes to brain injury are different in space and time
and can have immediate and positive effects on cell survival or long-
term delayed influence, affecting recovery. Indeed, it is still a matter of
debate whether reactive astrocytes are harmful or beneficial, since both
types of effects have been observed (Alilain et al., 2011; Voskuhl et al.,
2009). Different subtypes of reactive astrocytes, such as A1 and A2,
differ in their functions, depending on the nature, localization, and time
after injury (Liddelow and Barres, 2017). Our results suggest that
mGluR5 expressed in astrocytes (Arizono et al., 2014) could stimulate
their positive effects contributing to neuroprotection. Moreover, this
astrocyte activation also correlates with microglial activation, a me-
chanism that can contribute to identification and elimination of cellular
debris and neutrophils (Neumann et al., 2008; Milligan and Watkins,
2009; Cerbai et al., 2012; Lana et al., 2014) exerting a neuroprotective
effect. Indeed, although microglia has long been considered a major
contributor of postischemic inflammation, our data are in accordance
with the growing evidence that the inflammatory response may be
important for tissue repair (Madinier et al., 2009). It has been recently
demonstrated that while M1-type microglia release proinflammatory
and cytotoxic mediators, M2-type microglia can dampen inflammation
and promote tissue regeneration (Chawla et al., 2011). These data are
consistent with the concept that reactive gliosis may contribute to de-
crease of neuronal vulnerability (Burda and Sofroniew, 2014; Pekny
and Pekna, 2014; Lana et al., 2016). mGluRs are expressed on astro-
cytes and microglia and their activation under pathophysiological
conditions may shift microglia towards a pro-repair phenotype (Loane
et al., 2012; Loane et al., 2014). Further investigations are needed to
understand the mechanism underlying the mGluR5 involvement in as-
trocytes/microglia activation.
Fig. 5. Effects of mGlu5 receptor activation on the expression of GluA2-lacking
AMPA receptors in organotypic hippocampal slices exposed to OGD. The ex-
periments were carried out and drugs were added as shown in Fig. 5A. (A)
Schematic diagram showing that slices were incubated with drug during 30min
OGD and the subsequent recovery period of 12 h. (B) Activation of mGlu5 re-
ceptors prevents the down-regulation of the GluA2 AMPA receptor subunit
following OGD via the PI3K–Akt signalling pathway. Slices were exposed to
OGD for 30min and processed for Western blotting 12 h later. Top: A re-
presentative Western blot using a polyclonal goat antibody directed against
GluA2. α-Tubulin was used as loading control. The numbers on the right in-
dicate the estimated molecular mass (kDa). Bottom: quantitative analysis of
immunoreactive bands, showing that 30 min OGD induced 12 h later a sig-
nificant decrease in the expression of GluA2, that was significantly prevented
by the mGlu5 PAM VU0092273. The PI3K inhibitor LY294002 reverted the
effects of VU0092273. Data are expressed as percentage of GluA2 levels in
control untreated slices. Bars represent the mean ± SEM of three experiments.
**P < 0.01 vs. control (ANOVA + Tukey's w test). #P < 0.05 vs. OGD alone.
(C) NASPM attenuates OGD injury in a dose-dependent manner in organotypic
hippocampal slices. Data are expressed as percentage of OGD-induced PI
fluorescence in CA1 as observed 24 h after OGD. Values represent the
mean ± SEM of at least three experiments performed in quadruplicate.
*P < 0.05 vs. 30 min OGD alone (ANOVA + Tukey's w-test).
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Positive allosteric modulators of mGluR5 show functional selectivity
i.e. they have the potential to selectively activate distinct downstream
signalling pathway (Nickols and Conn, 2014). Here we investigated the
possible role of the PI3K signalling, one of the pathways activated by
group I mGluRs (Rong et al., 2003). Moreover, PI3K signalling leads to
Akt activation, which is well established to have neuroprotective ac-
tions (Datta et al., 1999; Kandel and Hay, 1999).
Consistent with this, the PI3K inhibitor LY294002 completely
abolished the neuroprotective effects of DHPG and VU0092273, sug-
gesting the crucial role of the mGluR5-PI3K-Akt signalling pathway in
their mechanism of action. Analysis of active phosphorylated Akt
(pAkt) showed that pAkt was activated by VU0092273 but not the
mGlu1 PAM VU0483605, indicating that activation of PI3K signalling
pathway is mGlu5 selective. Moreover, the pro-apoptotic kinase GSK3β
(Chen et al., 2004; Linseman et al., 2004) a downstream target of pAkt
(Pap and Cooper, 1998; Datta et al., 1999; Yamaguchi et al., 2004), also
showed increased phosphorylation. This is important because phos-
phorylated GSK3β (pGSK3β) is inactivated (Pap and Cooper, 1998;
Datta et al., 1999) so its inhibition can enhance cell survival.
Severe neurological insults trigger a ‘molecular switch’ that prevents
GluA2 AMPA receptor subunit gene expression in cells destined to die
(Pellegrini-Giampietro et al., 1997). The GluA2 hypothesis predicts that
Ca2+ entry through GluA2-lacking AMPA receptors in neurons that
normally express Ca2+-impermeable channels contributes to or causes
delayed cell death in response to endogenous glutamate (Pellegrini-
Giampietro et al., 1997; Liu et al., 2006; Henley and Wilkinson, 2016;
Koszegi et al., 2017).
We observed the GluA2 down-regulation 12 h after OGD injury,
revealing that this phenomenon precedes cell death, which occurs 24 h
later. Importantly, only mGluR5 PAM significantly prevents the GluA2
down-regulation induced by OGD injury. Moreover, when we measured
GluA2 protein levels in presence of PI3K inhibitor, the prevention of
GluA2 down-regulation was blocked when mediated by mGluR5 PAM,
suggesting that the mGluR5 triggers the GluA2 up-regulation through
the activation of PI3K signalling pathway, known to be also involved in
activation of nuclear transcription factors, that regulate the expression
of a large number of genes, critical for survival (Walton and Dragunow,
2000).
Thus, the mGluR5 exerts its neuroprotective effects against OGD
injury by activating the PI3K signalling pathway, through which it
triggers all the cascades which lead to block apoptotic processes and
promote the cell survival, and enhances the GluA2 up-regulation, pre-
venting the excitotoxic events which cause the delayed cell death.
Taken together our data demonstrate that in our OGD/recovery
model mGlu5 (i) activates the PI3K-Akt pathway to promote survival;
(ii) reduces GluA2 down-regulation which prevents the excytotoxic
cascade triggered by the increased Ca2+ influx due to GluA2-lacking
AMPA receptors; and (iii) contributes to reactive astrogliosis which can
assist in rescuing post-ischemic neurons from OGD-induced cell death.
Thus, we propose that selective activation/potentiation of mGlu5 sig-
nalling represents a promising strategy for the development of new
interventions to reduce or prevent ischemia-induced neuronal death.
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